Alzamend Neuro enters $3M at-the-market equity agreement with Ascendiant Capital

Alzamend Neuro, Inc.

Up to $3.0M in common stock may be sold periodically via ATM offering with sole agent Ascendiant Capital Markets.
Sales occur under effective shelf registration statement (Form S-3, File No. 333-273610) from August 2023.
Company controls timing, price, and volume; agent uses commercially reasonable efforts with no minimum commitment.
Common stock trades on Nasdaq under ALZN; shares sold will be freely tradable.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Alzamend Neuro, Inc. entered into At-the-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC valued at up to $3.0 million (effective 2026-03-06).

Action: entry
Agreement: atm program
Counterparty: Ascendiant Capital Markets, LLC
Value: up to $3.0 million
Effective: 2026-03-06

Exact text from the filing

On March 6, 2026, Alzamend Neuro, Inc. (the “ Company ”) entered into an At-the-Market Issuance Sales Agreement (the “ Sales Agreement ”) with Ascendiant Capital Markets, LLC, as sales agent (the “ Agent ”) to sell shares of its common stock, par value $0.0001 (the “ Common Stock ”), having an aggregate offering price of up to $3.0 million (the “ Shares ”) from time to time, through an “at the market offering”

View on SEC.gov

299 material agreements filed in the last 30 days. Browse all material agreements →

Alzamend Neuro, Inc. filing history →

Source: SEC EDGAR

accession 0001214659-26-002932

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.